Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
BioPharma Dive2d
The biopharma industry outlook on 2025: Uncertainty and change
The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...
Jim Cramer on Johnson & Johnson (JNJ): ‘Make Good Money Just By Reinvesting Their Juicy Dividends’
We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week’s Game Plan. In this article, we are ...